logo

Biopharmx Corp (BPMX)



Trade BPMX now with
  Date
  Headline
12/7/2017 4:26:10 PM BioPharmX Q3 Loss/share $0.05 Vs. Loss $0.12 Year Ago
11/8/2017 9:16:59 AM BioPharmX Receives Positive Feedback From FDA Regarding Design Of Planned Phase 3 Clinical Trial For BPX-01
9/13/2017 9:04:28 AM BioPharmX Q2 Loss Per Share $0.05 Vs Loss $0.18 Prior Year
7/13/2017 9:21:56 AM BioPharmX To Present Results Of Its Phase 2b Research Of BPX-01
6/22/2017 9:21:01 AM BioPharmX To Present Phase 2b Clinical Trial Acne Data At Alabama Dermatology Society Summer Symposium
6/13/2017 4:12:13 PM BioPharmX Q1 Loss/share $0.08 Vs. Loss $0.17 Year Ago
4/26/2017 9:01:58 AM BioPharmX Announces $5 Mln Offering
1/4/2017 9:17:02 AM BioPharmX Completes Enrollment Of BPX-01 Phase 2b OPAL Clinical Trial For Acne Vulgaris
12/13/2016 4:11:36 PM BioPharmX Q3 Loss/share $0.12 Vs. Loss $0.18 Year Ago
8/22/2016 8:03:46 AM BioPharmX Announces Final Phase 2a Trial Results Find BPX-01 Reduces Facial P. Acnes By More Than 90% In Four Weeks
6/29/2016 8:03:11 AM BioPharmX Unveils Positive Topline Phase 2a Trial Results For BPX-01 In Patients With Acne-Causing Bacteria
6/14/2016 4:06:25 PM BioPharmX Q1 Loss/share $0.17 Vs. Loss $0.33 Year Ago
4/26/2016 4:38:58 PM BioPharmX Q4 Loss/share $0.19 Vs. Loss $0.31 Year Ago
4/25/2016 8:07:46 AM BioPharmX Completes Enrollment For Its Phase 2a Study Of Novel Topical Minocycline Gel BPX-01
4/4/2016 8:35:58 AM Health Canada Approves BioPharmX Study Of Violet® Iodine